title: [Clinical efficacy and safety of rush immunotherapy in patients with allergic rhinitis].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of rush immunotherapy (RIT) for patients with persistent allergic rhinitis (AR).
  
  
  METHODS
  In this study, a total number of thirty three (33) patients who suffered mite allergic rhinitis were included. These patients completed one year subcutaneous immunotherapy (SCIT). Using RIT, the patients underwent the incremental dose phase in a week instead of 15 weeks in a conventional treatment procedure. The symptom scores, visual analog scale (VAS), appropriate medication score, total blood serum IgE, dermatophagoides pteronyssinus specificity IgG4, mite allergy skin prick test (SPT), dermatophagoides farinae nasal provocation test (NPT) and the incidence of adverse reactions were used to evaluate the efficiency and safety of RIT.
  
  
  RESULTS
  After one year SCIT treatment, the symptom score and VAS scores were significantly decreased, the corresponding medication usage was significantly reduced (8.91 ± 1.84, 20.64 ± 6.99 vs. 4.97 ± 2.92, 11.94 ± 7.21, t value was 9.15, 7.11, both P < 0.001) and the cutaneous reactions to mite allergen were significantly decreased (P < 0.001) as well. However, dermatophagoides pteronyssinus-specific serum IgG4 increased significantly (Z = -4.517, P < 0.001). The concentration of dermatophagoides farinae nasal provocation test (NPT) was significantly increased. After the treatment, the number of patients who had positive reactions to high concentration nasal provocation test (NPT) increased (χ² = 1.93, P = 0.38). During the treatment, all the patients experienced local reactions, and specifically there were four patients got general reactions.
  
  
  CONCLUSIONS
  RIT is safe and effective. It shortened the incremental dose phase remarkably. NPT is a good indicator for diagnosing allergic rhinitis and evaluating the efficacy of the treatment.
authors.affiliation: Department of Otorhinolaryngology, Wuxi Traditional Chinese Medicine Hospital, Wuxi 214071, China; Email: xieweiwxzyy@163.com.
authors.forename: Wei
authors.initials: W
authors.lastname: Xie
authors.affiliation: Department of Otorhinolaryngology, Wuxi Traditional Chinese Medicine Hospital, Wuxi 214071, China.
authors.forename: Hanzhong
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Otorhinolaryngology, Wuxi Traditional Chinese Medicine Hospital, Wuxi 214071, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of Otorhinolaryngology, Wuxi Traditional Chinese Medicine Hospital, Wuxi 214071, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
mesh_terms: D000485:Allergens / Q000276:immunology; D000818:Animals; D039741:Antigens, Dermatophagoides / Q000276:immunology; D040001:Dermatophagoides farinae; D040002:Dermatophagoides pteronyssinus; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D007279:Injections, Subcutaneous; D009299:Nasal Provocation Tests; D039981:Pyroglyphidae; D065631:Rhinitis, Allergic / Q000628:therapy*; D012680:Sensitivity and Specificity; D012882:Skin Tests; D016896:Treatment Outcome
chemical_list: D000485:Allergens; D039741:Antigens, Dermatophagoides; D007074:Immunoglobulin G